UK NICE OKs Melanoma Combo Treatment From Array/Pierre Fabre
Executive Summary
Array BioPharma/Pierre Fabre’s combination treatment for metastatic melanoma has received NICE's go-ahead for funding under the national health service in England and Wales.
You may also be interested in...
Melanoma Combos Get Mixed Reception From German HTA Body
Germany’s IQWiG says Mekinist plus Tafinlar offers a “considerable” added benefit in melanoma after surgery, but Braftovi plus Mektovi has not shown an additional benefit over comparator therapy in unresectable or metastatic melanoma.
Pierre Fabre Set To Shake Up EU Melanoma Market
Having just got the nod for the combination of Braftovi and Mektovi, the French company believes the strength of its overall survival data will see the therapy successfully compete with other BRAF/MEK combos and immunotherapies for melanoma.
Will Pierre Fabre and Array Have Best-In-Class MEK/BRAF Inhibitor?
Updated results from the COLUMBUS trial in BRAF-mutant advanced melanoma presented at ASCO revealed stellar overall survival data for the combination of encorafenib and binimetinib. Rivals Novartis and Roche will have noted that approval in the US is expected before the end of June.